Mark L. Lipman

4.2k total citations · 1 hit paper
58 papers, 3.3k citations indexed

About

Mark L. Lipman is a scholar working on Surgery, Transplantation and Molecular Biology. According to data from OpenAlex, Mark L. Lipman has authored 58 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 11 papers in Transplantation and 10 papers in Molecular Biology. Recurrent topics in Mark L. Lipman's work include Renal Transplantation Outcomes and Treatments (11 papers), Organ Transplantation Techniques and Outcomes (6 papers) and Dialysis and Renal Disease Management (5 papers). Mark L. Lipman is often cited by papers focused on Renal Transplantation Outcomes and Treatments (11 papers), Organ Transplantation Techniques and Outcomes (6 papers) and Dialysis and Renal Disease Management (5 papers). Mark L. Lipman collaborates with scholars based in Canada, United States and France. Mark L. Lipman's co-authors include Ernesto L. Schiffrin, Johannes F.E. Mann, Terry B. Strom, Michael Shapiro, Martha Pavlakis, William Harmon, B Zanker, Lauro Vasconcellos, Jürgen Strehlau and A. Stevens and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Mark L. Lipman

56 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chronic Kidney Disease

2007 1.1k citations Ernesto L. Schiffrin, Mark L. Lipman et al. profile →

Peers

Countries citing papers authored by Mark L. Lipman

Since Specialization

Citations

This map shows the geographic impact of Mark L. Lipman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark L. Lipman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark L. Lipman more than expected).

Fields of papers citing papers by Mark L. Lipman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark L. Lipman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark L. Lipman. The network helps show where Mark L. Lipman may publish in the future.

Co-authorship network of co-authors of Mark L. Lipman

This figure shows the co-authorship network connecting the top 25 collaborators of Mark L. Lipman. A scholar is included among the top collaborators of Mark L. Lipman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark L. Lipman. Mark L. Lipman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis 2025 ·Clinical Pharmacokinetics ·(unknown), Mark L. Lipman, Thomas A. Mavrakanas, Zoubir Djerada	0
2	SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis 2022 ·Journal of Clinical Investigation ·Dibyendu K. Panda, Xiuying Bai, Yan Zhang, (unknown), Antonis E. Koromilas, Mark L. Lipman, Andrew C. Karaplis	16
3	A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes 2019 ·Case Reports in Endocrinology ·(unknown), Mark L. Lipman, Denny Laporta, Oriana Hoi Yun Yu	9
4	Psychosocial Distress and Health Service Utilization in Patients Undergoing Hemodialysis: A Prospective Study 2018 ·Psychosomatics ·(unknown), István Mucsi, Madeline Li, (unknown), Mark L. Lipman, Karl Looper, Márta Novák, Soham Rej	16
5	Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management 2018 ·BMC Nephrology ·(unknown), Ahmed AlTurki, (unknown), Mark L. Lipman	10
6	Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients 2017 ·Journal of the American Society of Nephrology ·Thomas A. Mavrakanas, Caroline Samer, Sharon J. Nessim, Gershon Frisch, Mark L. Lipman	158
7	Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers 2017 ·Canadian Journal of Diabetes ·Thomas A. Mavrakanas, Mark L. Lipman	3
8	The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study 2015 ·BMC Nephrology ·(unknown), Ahsan Alam, Mark L. Lipman, Sharon J. Nessim	17
9	Pretransplantation Recipient Regulatory T cell Suppressive Function Predicts Delayed and Slow Graft Function after Kidney Transplantation 2014 ·Transplantation ·(unknown), (unknown), (unknown), Shuqing Liu, René P. Michel, Mark L. Lipman, István Mucsi, Marcelo Cantarovich, Jean Tchervenkov, Steven Paraskevas	13
10	What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy? 2012 ·Current Cardiology Reports ·Mark L. Lipman, Ernesto L. Schiffrin	10
11	Suppression of the Cell-Mediated Immune Response by a Fas-Immunoglobulin Fusion Protein 2006 ·Transplantation ·(unknown), Barbara Young, Mark L. Lipman	1
12	Assessment of different carbon sources and delivery techniques to promote an in situ reactive zone for bioprecipitation of metals in groundwater 2005 ·IAHS-AISH publication ·Bradley M. Patterson, (unknown), (unknown), (unknown), Greg B. Davis, Mark L. Lipman, (unknown), Allan J. McKinley, Andrew W. Rate	1
13	Donor-specific portal transfusion augments microchimerism in a porcine model of small bowel transplantation 2000 ·Transplantation Proceedings ·Nancy Morin, (unknown), Mark L. Lipman, (unknown), Jean Tchervenkov, Peter Metrakos	6
14	IMMUNE-ACTIVATION GENE EXPRESSION IN CLINICALLY STABLE RENAL ALLOGRAFT BIOPSIES: MOLECULAR EVIDENCE FOR SUBCLINICAL REJECTION1,2 1998 ·Transplantation ·Mark L. Lipman, (unknown), John Jeffery, James Gough, Rachel M. McKenna, Paul C. Grimm, David N. Rush	77
15	Cloning of Human PEXcDNA 1998 ·Journal of Biological Chemistry ·Mark L. Lipman, Dibyendu K. Panda, H.P.J. Bennett, Janet E. Henderson, Elizabeth Shane, (unknown), David Goltzman, Andrew C. Karaplis	106
16	Use of intragraft gene expression in the diagnosis of kidney allograft rejection. 1996 ·PubMed ·Martha Pavlakis, J. Strehlau, Mark L. Lipman, Terry B. Strom	3
17	INTRAGRAFT IL-15 TRANSCRIPTS ARE INCREASED IN HUMAN RENAL ALLOGRAFT REJECTION1 1996 ·Transplantation ·Martha Pavlakis, J. Strehlau, Mark L. Lipman, Michael Shapiro, Włodzimierz Maśliński, Terry B. Strom	90
18	Partial mediation of glucocorticoid antiproliferative effects by lipocortins 1996 ·The Journal of Immunology ·WY Almawi, (unknown), A. Christopher Stevens, Mark L. Lipman, Christian Barth, T B Strom	26
19	Heightened intragraft CTL gene expression in acutely rejecting renal allografts. 1994 ·The Journal of Immunology ·Mark L. Lipman, A. Stevens, Terry B. Strom	142
20	Tumor necrosis factor-?, interleukin-1?, and interleukin-6 expression in inflammatory bowel disease 1992 ·Digestive Diseases and Sciences ·Chris Stevens, Gerd Walz, (unknown), Mark L. Lipman, B Zanker, (unknown), Donald A. Antonioli, Mark A. Peppercorn, Terry B. Strom	280

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact